Lantheus Holdings (LNTH) Research & Development (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Research & Development came in at $39.4 million in Q1 2026, down 7.35% year-on-year from $42.5 million in Q1 2025, and up 132.5% on a QoQ basis from -$121.2 million in Q4 2025.
Lantheus Holdings (LNTH) Research & Development (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Research & Development data on file, last reported at $39.4 million in Q1 2026.
- On a quarterly basis, Research & Development fell 7.35% year-over-year to $39.4 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a 97.15% decrease from a year earlier, with the FY2025 full-year figure at $11.2 million, down 93.34% from the prior year.
- Research & Development for Q1 2026 stood at $39.4 million, up from -$121.2 million in the prior quarter.
- Over the last five years, Research & Development for LNTH reached as high as $220.5 million in Q4 2022 and fell as low as -$121.2 million in Q4 2025.
- Historically, Research & Development has averaged $43.0 million across 5 years, with a median of $37.4 million in 2023.
- Across the five-year window, Research & Development soared 5568.51% in 2022 and plunged 191.73% in 2025, its largest moves.
- Year by year, Research & Development stood at $220.5 million in 2022, then sank by 63.34% to $80.9 million in 2023, then soared by 63.38% to $132.1 million in 2024, then plunged by 191.73% to -$121.2 million in 2025, then soared by 132.5% to $39.4 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $39.4 million in Q1 2026, -$121.2 million in Q4 2025, and $48.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 39.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.38 Mn |
| Dec 31, 2025 | -121.17 Mn |
| Sep 30, 2025 | 48.03 Mn |
| Jun 30, 2025 | 41.04 Mn |
| Mar 31, 2025 | 42.50 Mn |
| Dec 31, 2024 | 132.10 Mn |
| Sep 30, 2024 | 36.00 Mn |
| Jun 30, 2024 | 45.04 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Dec 31, 2023 | 80.85 Mn |
| Sep 30, 2023 | 37.40 Mn |
| Jun 30, 2023 | 15.90 Mn |
| Mar 31, 2023 | 32.62 Mn |
| Dec 31, 2022 | 220.55 Mn |
| Sep 30, 2022 | 25.41 Mn |
| Jun 30, 2022 | 14.74 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | 11.25 Mn |
| Jun 30, 2021 | 12.06 Mn |